PT-141 injection is an FDA-approved bremelanotide shot for HSDD in premenopausal women. Learn how it works, typical dosing, side effects, and safety.
PT-141 injection is a prescription subcutaneous shot of bremelanotide, a melanocortin receptor agonist the FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved dose is 1.75 mg injected under the skin of the abdomen or thigh, typically about 45 minutes before anticipated sexual activity. It is not a hormone, not an over-the-counter supplement, and not a treatment for erectile dysfunction.
What Is PT-141 Injection?
Bremelanotide is a synthetic peptide related to alpha-melanocyte-stimulating hormone. It works in the brain by activating melanocortin receptors, especially MC4R, which are tied to desire and arousal rather than to blood flow alone.
Because the mechanism is central, researchers have studied bremelanotide in both women and men. The FDA-approved indication, however, remains narrow: generalized HSDD in premenopausal women.
How It Works and What to Expect
After a subcutaneous shot, bremelanotide reaches peak blood levels in roughly 30 to 60 minutes. That timeline is why the label tells patients to dose about 45 minutes before sexual activity.
Unlike PDE5 inhibitors, bremelanotide does not directly relax genital blood vessels. It signals through the central nervous system, so individual responses vary widely.
Anyone researching pt 141 injection has likely noticed that the drug has poor oral bioavailability, which is why it is not sold as a pill. That leaves injection and intranasal delivery as the two routes people discuss most.
PT-141 Injection Dosage and Instructions
The label dose is 1.75 mg, or 0.175 mL of the 10 mg/mL solution, injected subcutaneously into the abdomen or thigh. Inject at least two inches away from the navel, and rotate sites to limit irritation.
Most people searching for pt-141 injection dosage want to know whether the amount can be adjusted. The approved answer is no: there is no titration, and 1.75 mg is the only labeled dose.
Detailed pt-141 injection instructions come with the manufacturer's single-dose pen, and the key steps are to use a fresh needle, inject into the abdomen or thigh, and dispose of the needle safely.
| Parameter | Approved detail |
|---|---|
| Dose | 1.75 mg subcutaneous |
| Timing | About 45 minutes before activity |
| Maximum frequency | One dose per 24 hours; no more than 8 doses per month |
| Injection site | Abdomen or thigh |
| Approved population | Premenopausal women with HSDD |
PT-141 Nasal Spray vs Injection
Bremelanotide was first tested as a nasal spray, and an intranasal version reached late-stage trials before regulators declined to approve it over blood pressure concerns and inconsistent absorption. No nasal bremelanotide product is currently approved in the United States.
When comparing pt-141 nasal spray vs injection, the injected form has the advantage of predictability because it delivers a fixed, measurable dose. The nasal route is easier to administer, but it produces more variable blood levels and more local side effects such as nasal irritation and congestion.
| Feature | Injection (Vyleesi) | Nasal spray |
|---|---|---|
| FDA status | Approved in 2019 for premenopausal HSDD | Not approved |
| Typical dose | 1.75 mg subcutaneous | Variable; often around 10 mg in older research |
| Absorption | Predictable | Inconsistent |
| Common local issues | Injection site reactions | Nasal irritation, congestion |
Side Effects and Safety Considerations
Nausea is the most common side effect and was reported by a large share of participants in clinical trials. Flushing, headache, vomiting, and injection site reactions are also frequent.
Bremelanotide can raise blood pressure for a few hours after a dose. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
Focal hyperpigmentation, or darkening of the skin, gums, or face, has been reported with frequent use. This effect may not fully reverse after the drug is stopped.
PT-141 injection is not approved for men, for postmenopausal women, or for daily use. Off-label use exists, but long-term safety data in those groups are limited.
Anyone taking blood pressure medication, nitrates, or other vasoactive drugs should clear bremelanotide with a clinician first. Alcohol may worsen nausea in some users.
Research Vials and Legal Status
Bremelanotide is also sold as a research chemical, often as a pt-141 bremelanotide injection 20mg vial of lyophilized powder that must be reconstituted before use. These products carry a research-use-only label and are not intended for human consumption.
Purity, sterility, and actual peptide content vary widely among unregulated suppliers. In the United States, bremelanotide for human use requires a prescription dispensed by a licensed pharmacy.
Who Should Talk to a Clinician First
- People with high or uncontrolled blood pressure, or any history of heart disease
- Anyone taking blood pressure medications or nitrates
- Women who are pregnant, breastfeeding, or postmenopausal
- People who have had severe nausea with similar medications
A clinician can confirm whether bremelanotide is appropriate and screen for interactions. PT-141 injection is a prescription drug, not a wellness product, and it should not be started without medical guidance.
The Bottom Line
PT-141 injection is an FDA-approved bremelanotide shot for premenopausal women with hypoactive sexual desire disorder. The labeled dose is 1.75 mg subcutaneously about 45 minutes before activity, capped at eight doses per month.
The nasal spray version is not FDA-approved, and research-grade vials are not substitutes for a prescribed product. Anyone considering bremelanotide should review blood pressure risks and side effects with a healthcare professional first.
Frequently Asked Questions
Is PT-141 injection FDA-approved?
Yes. The FDA approved bremelanotide injection under the brand name Vyleesi in 2019 for hypoactive sexual desire disorder in premenopausal women. It is not approved for men, for postmenopausal women, or for casual recreational use. Nasal and research-grade versions of bremelanotide are not FDA-approved.
How often can you use PT-141 injection?
The label allows one 1.75 mg dose in any 24-hour period and no more than eight doses per month. Doses are given about 45 minutes before anticipated sexual activity. Exceeding the labeled frequency increases the risk of nausea and skin darkening.
What are the most common side effects of PT-141 injection?
Nausea is the most frequently reported side effect, followed by flushing, headache, vomiting, and injection site reactions. Bremelanotide can also raise blood pressure for several hours after a dose. It is contraindicated in people with uncontrolled hypertension or known heart disease.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.